Journal
PHARMACOTHERAPY
Volume 27, Issue 6, Pages 874-887Publisher
WILEY
DOI: 10.1592/phco.27.6.874
Keywords
pharmacogenetics; beta-blockers; hypertension; heart failure; atenolol; metoprolol; beta(1)-adrenergic receptor gene; ADRB1; cytochrome P450 2D6 gene; CYP2D6
Categories
Ask authors/readers for more resources
beta-Blockers are an important cardiovascular drug class, recommended as first-line treatment of numerous diseases such as heart failure, hypertension, and angina, as well as treatment after myocardial infarction. However, responses to a beta-blocker are variable among patients. Results of numerous studies now suggest that genetic polymorphisms may contribute to variability in responses to beta-blockers. This review summarizes the pharmacogenetic data for beta-blockers in patients with various diseases and discusses the potential implications of beta-blocker pharmacogenetics in clinical practice.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available